Because of the pro-fibrotic role HIFs, therapeutic inhibition of HIF-1α and/or HIF-2α may attenuate fibrosis and slow its progression to cirrhosis and HCC. The gene discussed is EPAS1; the disease is hepatocellular carcinoma.